Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (251-260 of 274) with videos related to

Pageof 28
Sort By:
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
Mayo Clinic Proceedings|June 26, 2019
Oncolytic Measles Virotherapy and Opposition to Measles VaccinationStephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Haematologica|May 20, 2017
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtypeCarolina Schinke, Antje Hoering, Hongwei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
Blood Advances|December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseFrits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Cell Reports. Medicine|October 5, 2023
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myelomaYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Pageof 28

Showing results (251-260 of 274) with videos related to

Sort By:
Pageof 28
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi, Roxanne Steinle, Balaji Balasa, et al.
Mayo Clinic Proceedings|June 26, 2019
Oncolytic Measles Virotherapy and Opposition to Measles VaccinationStephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Haematologica|May 20, 2017
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtypeCarolina Schinke, Antje Hoering, Hongwei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
Blood Advances|December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseFrits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Cell Reports. Medicine|October 5, 2023
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myelomaYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Pageof 28